Advances in Targeted Drugs for Allergic Diseases
Allergic diseases, including asthma, allergic rhinitis, atopic dermatitis, and other hypersensitivity disorders, have seen significant advancements in treatment strategies over the past two decades. The development of targeted drugs, particularly monoclonal antibodies, has revolutionized the management of these conditions by offering more precise and effective therapeutic options. This article provides a comprehensive overview of the key targeted drugs currently in clinical use or under investigation for allergic diseases, focusing on their mechanisms of action, efficacy, safety profiles, and clinical applications.
IgE-Targeted Drugs
Immunoglobulin E (IgE) plays a central role in the pathogenesis of allergic diseases by triggering an allergic cascade reaction. This reaction is initiated when IgE binds to its high-affinity receptor (FcεRI) on mast cells and basophils, leading to the release of inflammatory mediators such as histamine, leukotrienes, and cytokines. Two monoclonal antibodies targeting IgE have been developed: omalizumab and ligelizumab.
Omalizumab is a humanized monoclonal antibody that binds to the Cε3 domain of IgE, preventing its interaction with FcεRI. This inhibition effectively blocks the allergic cascade and reduces the symptoms of allergic asthma, particularly in patients with moderate-to-severe disease. Clinical trials have demonstrated that omalizumab significantly reduces asthma exacerbations and improves lung function in adults, adolescents, and children. However, its efficacy is limited in patients with very high levels of IgE (above 700 U/mL). Omalizumab has also shown promise in treating severe refractory atopic dermatitis, offering a safe and effective therapeutic option for this challenging condition.
Ligelizumab (QGE031) is another humanized monoclonal antibody targeting IgE, but with a higher affinity for the Cε3 domain compared to omalizumab. This increased affinity allows ligelizumab to more effectively inhibit IgE in patients with elevated IgE levels. Early clinical data suggest that ligelizumab may offer superior efficacy in controlling allergic asthma and other IgE-mediated diseases, although further studies are needed to confirm these findings.
IL-4 and IL-4R-Targeted Drugs
Interleukin-4 (IL-4) is a key cytokine involved in the regulation of Th2 immune responses, IgE production, and the pathogenesis of atopic diseases such as asthma, allergic rhinitis, and atopic dermatitis. Several monoclonal antibodies targeting IL-4 or its receptor (IL-4R) have been developed, including pascolizumab, pitrakinra, altrakincept, and dupilumab.
Pascolizumab is a humanized monoclonal antibody that inhibits IL-4 signaling, thereby reducing Th2 cell activation and IgE production. Despite demonstrating good safety and tolerability in clinical trials, pascolizumab has not shown significant efficacy in alleviating asthma symptoms, limiting its clinical utility.
Pitrakinra is a recombinant monoclonal antibody that competitively inhibits the binding of IL-4 and IL-13 to the IL-4Rα subunit. This dual inhibition reduces Th2-mediated allergic inflammation and has been shown to improve asthma control in patients with allergic asthma. Pitrakinra can be administered via injection or inhalation, with both routes demonstrating excellent tolerability and efficacy in reducing airway hyperresponsiveness and eosinophilic inflammation.
Dupilumab is a monoclonal antibody that targets the IL-4Rα subunit, effectively blocking the signaling of both IL-4 and IL-13. This dual inhibition has proven highly effective in treating moderate-to-severe asthma, particularly in patients with persistent symptoms despite standard therapy. Dupilumab significantly reduces asthma exacerbations, improves lung function, and enhances the quality of life for patients. Additionally, dupilumab has shown remarkable efficacy in treating moderate-to-severe atopic dermatitis, with clinical trials demonstrating significant improvements in skin lesions and overall disease severity. Common adverse effects include injection site reactions, nasopharyngitis, conjunctivitis, nausea, and headache, but these are generally mild and manageable.
IL-5 and IL-5R-Targeted Drugs
Interleukin-5 (IL-5) is a cytokine that plays a critical role in the growth, differentiation, recruitment, activation, and survival of eosinophils, which are key effector cells in allergic inflammation and asthma. Three monoclonal antibodies targeting IL-5 or its receptor (IL-5R) have been developed: mepolizumab, reslizumab, and benralizumab.
Mepolizumab is a humanized monoclonal antibody that binds to IL-5, preventing its interaction with the IL-5R on eosinophils. This inhibition significantly reduces eosinophil levels and has been shown to decrease asthma exacerbations in patients with severe eosinophilic asthma. Mepolizumab is well-tolerated and has also been used to treat hypereosinophilic syndrome in children, offering a safe and effective therapeutic option for this condition.
Reslizumab is another humanized monoclonal antibody targeting IL-5, used as a maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 18 years and older. Reslizumab reduces the frequency of asthma exacerbations and improves lung function and quality of life in patients with poorly controlled eosinophilic asthma. Common adverse effects include asthma exacerbation, nasopharyngitis, oropharyngeal pain, myalgia, and upper respiratory tract infections.
Benralizumab is a non-glycosylated monoclonal antibody that targets the IL-5Rα subunit, inducing rapid and direct eosinophil depletion through antibody-dependent cell-mediated cytotoxicity (ADCC). Benralizumab has demonstrated excellent efficacy in reducing asthma exacerbations and improving lung function in patients with severe, uncontrolled eosinophilic asthma. The most common adverse effects are nasopharyngitis, asthma exacerbation, and upper respiratory tract infections.
IL-13-Targeted Drugs
Interleukin-13 (IL-13) is a cytokine produced by activated Th2 cells and mast cells that plays a central role in the pathogenesis of allergic asthma and atopic dermatitis. IL-13 signaling through the IL-13Rα1 and IL-4Rα complex activates downstream pathways that lead to airway hyperresponsiveness, mucus production, and inflammation. Two monoclonal antibodies targeting IL-13 have been developed: lebrikizumab and tralokinumab.
Lebrikizumab is a monoclonal antibody that inhibits the binding of IL-13 to the IL-13Rα1 subunit, thereby reducing Th2-mediated inflammation. Clinical trials have shown that lebrikizumab significantly decreases periostin levels in the blood of patients with Th2-high asthma and improves the eczema area and severity index (EASI) in patients with atopic dermatitis. However, further studies are needed to establish its efficacy and safety in allergic rhinitis.
Tralokinumab is another monoclonal antibody targeting IL-13, with clinical trials demonstrating its efficacy in reducing symptoms of moderate-to-severe allergic asthma. However, like lebrikizumab, tralokinumab has not been extensively studied in allergic rhinitis, and more research is needed to determine its full therapeutic potential.
TSLP-Targeted Drugs
Thymic stromal lymphopoietin (TSLP) is a cytokine produced by epithelial cells that plays a key role in initiating and maintaining Th2-mediated allergic inflammation. TSLP is implicated in the pathogenesis of allergic rhinitis, asthma, and atopic dermatitis. Tezepelumab is a monoclonal antibody targeting TSLP, with clinical trials demonstrating its efficacy in reducing asthma exacerbations in patients with severe asthma. However, tezepelumab is less effective in non-Th2 asthma, and further studies are needed to confirm its efficacy in atopic dermatitis and allergic rhinitis.
Th2 Cytokine Inhibitors
Th2 cells are central to the pathogenesis of allergic diseases, producing cytokines such as IL-4, IL-5, and IL-13 that drive allergic inflammation. Suplatast tosilate is a selective Th2 inhibitor that reduces the production of IL-4 and IL-5, thereby alleviating airway inflammation and improving asthma control. Suplatast tosilate has been used in the early prevention and treatment of allergic diseases such as asthma, allergic rhinitis, and atopic dermatitis. It is particularly effective in preventing asthma symptoms in children during the autumn season and has shown efficacy in reducing atopic dermatitis symptoms. Adverse effects are rare and include transient liver or kidney dysfunction.
Conclusion
The development of targeted drugs for allergic diseases has significantly advanced the treatment options available for patients with asthma, allergic rhinitis, atopic dermatitis, and other hypersensitivity disorders. Monoclonal antibodies targeting IgE, IL-4, IL-5, IL-13, TSLP, and Th2 cytokines have demonstrated remarkable efficacy in reducing disease symptoms, improving quality of life, and minimizing the need for systemic corticosteroids. However, the choice of targeted therapy should be based on a thorough evaluation of the patient’s medical history, laboratory findings, and disease severity to ensure optimal outcomes. As research continues, further advancements in targeted therapies are expected to provide even more effective and personalized treatment options for patients with allergic diseases.
doi.org/10.1097/CM9.0000000000001349
Was this helpful?
0 / 0